NR3C1 and acute lymphoblastic leukemia: GCs are a key component of ALL treatment protocols, and the roles of NR3C1 and BTG1 expression and perturbation have been widely analyzed in the REH cell line (van Galen et al, 2010; van der Zwet et al, 2021).